These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16892378)

  • 41. Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists.
    Drizin I; Gomtsyan A; Bayburt EK; Schmidt RG; Zheng GZ; Perner RJ; DiDomenico S; Koenig JR; Turner SC; Jinkerson TK; Brown BS; Keddy RG; McDonald HA; Honore P; Wismer CT; Marsh KC; Wetter JM; Polakowski JS; Segreti JA; Jarvis MF; Faltynek CR; Lee CH
    Bioorg Med Chem; 2006 Jul; 14(14):4740-9. PubMed ID: 16621571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons.
    Niiyama Y; Kawamata T; Yamamoto J; Omote K; Namiki A
    Neuroscience; 2007 Aug; 148(2):560-72. PubMed ID: 17656027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo.
    Christoph T; Grünweller A; Mika J; Schäfer MK; Wade EJ; Weihe E; Erdmann VA; Frank R; Gillen C; Kurreck J
    Biochem Biophys Res Commun; 2006 Nov; 350(1):238-43. PubMed ID: 16996476
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of piperidine carboxamide TRPV1 antagonists.
    Cheung WS; Calvo RR; Tounge BA; Zhang SP; Stone DR; Brandt MR; Hutchinson T; Flores CM; Player MR
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4569-72. PubMed ID: 18662879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TRPV1 expression-dependent initiation and regulation of filopodia.
    Goswami C; Hucho T
    J Neurochem; 2007 Nov; 103(4):1319-33. PubMed ID: 17714453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The analgesic drug, tramadol, acts as an agonist of the transient receptor potential vanilloid-1.
    Marincsák R; Tóth BI; Czifra G; Szabó T; Kovács L; Bíró T
    Anesth Analg; 2008 Jun; 106(6):1890-6. PubMed ID: 18499628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TRPV1 antagonists: the challenges for therapeutic targeting.
    Khairatkar-Joshi N; Szallasi A
    Trends Mol Med; 2009 Jan; 15(1):14-22. PubMed ID: 19097938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
    Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
    J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis of benzamide derivatives as TRPV1 antagonists.
    Shishido Y; Jinno M; Ikeda T; Ito F; Sudo M; Makita N; Ohta A; Iki-Taki A; Ohmi T; Kanai Y; Tamura T; Shimojo M
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1072-8. PubMed ID: 18155908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray.
    Terzian AL; Aguiar DC; Guimarães FS; Moreira FA
    Eur Neuropsychopharmacol; 2009 Mar; 19(3):188-95. PubMed ID: 19064314
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
    Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct activation of transient receptor potential vanilloid 1(TRPV1) by diacylglycerol (DAG).
    Woo DH; Jung SJ; Zhu MH; Park CK; Kim YH; Oh SB; Lee CJ
    Mol Pain; 2008 Oct; 4():42. PubMed ID: 18826653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine.
    Sadofsky LR; Campi B; Trevisani M; Compton SJ; Morice AH
    Exp Lung Res; 2008 Dec; 34(10):681-93. PubMed ID: 19085565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
    Gunthorpe MJ; Chizh BA
    Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis of oxazolo[4,5-c]quinoline TRPV1 antagonists.
    Voight EA; Daanen JF; Kort ME
    J Org Chem; 2010 Dec; 75(24):8713-5. PubMed ID: 21090730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of TRPV1 antagonist ABT-116.
    Brown BS; Keddy R; Perner RJ; DiDomenico S; Koenig JR; Jinkerson TK; Hannick SM; McDonald HA; Bianchi BR; Honore P; Puttfarcken PS; Moreland RB; Marsh KC; Faltynek CR; Lee CH
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3291-4. PubMed ID: 20457518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analgesic dipeptide derivatives. 4. Linear and cyclic analogues of the analgesic compounds arginyl-2-[(o-nitrophenyl)sulfenyl]tryptophan and lysyl-2-[(o-nitrophenyl)sulfenyl]tryptophan.
    Garcia-López MT; González-Muñiz R; Molinero MT; Del Rio J
    J Med Chem; 1988 Feb; 31(2):295-300. PubMed ID: 3339602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases.
    Lim KM; Park YH
    Arch Pharm Res; 2012 Mar; 35(3):393-6. PubMed ID: 22477184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Advance in studies on TRPV1 and analgesic effect of traditional Chinese medicines].
    Liu XL; Lv C; Zhang WS
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(10):1757-60. PubMed ID: 25282877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of potent transient receptor potential vanilloid 1 antagonists: design and synthesis of phenoxyacetamide derivatives.
    Takahashi E; Hirano N; Nagahara T; Yoshikawa S; Momen S; Yokokawa H; Hayashi R
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3154-6. PubMed ID: 23632270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.